Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Q&A: The new COVID vaccine booster is coming. Should you get it?

The COVID-19 vaccine is getting an upgrade.

Tribune News Service

Bayer initiates asundexian Phase III study program

Germany's Bayer said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.

Reuters

AstraZeneca boss uncertain if yearly Covid-19 boosters for healthy are good use of resources

The chief executive officer believes most of the vaccinated population now has a "foundation immunity against severe disease"

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Virginia health officials projecting first decrease in overdose deaths since before the pandemic

NORFOLK, Va. — New data on fatal drug overdoses in Virginia suggests this year could be the first time there’s been a decrease in deaths since 2018.

Tribune News Service

AstraZeneca boss unsure if annual Covid-19 boosters are good use of resources

Chief executive officer Pascal Soriot said he believes most of the vaccinated population has a ‘foundation immunity against severe disease’.

The Independent UK

Indian pharma company taken to court over freebies to doctors

Indian authorities are probing allegations that a drug company bribed doctors to promote its anti-fever pills – the latest controversy involving the country’s pharmaceuticals industry.

Radio France Internationale

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

Asharq Al-Awsat

Should You Buy Eargo After the FDA Ruling on Hearing Aids?

Hearing aid maker Eargo (EAR) reported disappointing second-quarter results. And analysts seem bearish about the company’s growth prospects. However, EAR climbed considerably following the FDA approval for over-the-counter hearing aid sales. After gaining nearly 198% over the past month, is EAR still a buy now? Read more to find out….

StockNews.com

US Covid vaccine maker Moderna suing rivals Pfizer and BioNTech over jab

The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016

Wales Online

Pfizer asks EU drug regulator to OK tweaked COVID vaccine

Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants

The Independent UK

Is This Eye Care Stock a Buy as It Strikes $770M Buyout?

Swiss eye care company Alcon (ALC) recently announced that it would acquire Aerie Pharmaceuticals (AERI) for $770 million. The deal is expected to help bolster ALC’s expansion into the ophthalmic pharmaceutical space. So, will it be wise to invest in the stock now? Read on to learn our view….

StockNews.com

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

The vaccine maker said it had filed patent infringement lawsuits in the US and Germany.

The Independent UK

Moderna sues Pfizer/BioNTech alleging patent infringement over Covid vaccine

Moderna seeks unspecified damages in lawsuit over rivals’ jab

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

Bangkok Post

Thonburi Healthcare chairman resigns after market ban

Dr Boon Vanasin, the founder and chairman of Thonburi Healthcare Group (THG), is resigning from the company’s board as he faces a market ban in connection with claims he made last year about the purchase of Pfizer coronavirus vaccines.

Tribune News Service

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Bangkok Post

Moderna sues Pfizer over Covid vaccine

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

The Independent UK

Moderna sues Pfizer over patents behind COVID-19 vaccine

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Moderna sues Pfizer-BioNTech accusing them of copying Covid shot technology

‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says

StockNews.com

Is Pfizer a Buy Before New Omicron Boosters Roll Out?

Pharmaceutical giant Pfizer’s (PFE) omicron-targeted booster doses could soon be authorized this fall. The company has benefited largely from the pandemic and its vaccine rollouts. Now let’s find out if PFE is a Buy now as it prepares to roll out its booster doses….

Axios

Moderna sues Pfizer, BioNTech over COVID-19 vaccine

The lawsuit seeks unspecified monetary damages for patent infringement.

Reuters

Australian police seize record $1.1 billion of crystal meth

Australian police said on Friday it had seized some A$1.6 billion ($1.1 billion) worth of crystal meth, also known as 'ice', concealed within marble stones in several sea freight containers, in what it said was the biggest ever haul of the drug in the country.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

ABC News

NSW Police seize record 1.8 tonnes of ice at Sydney's Port Botany

NSW Police say they have busted/ intercepted/ seized Australia's biggest known ice shipment, which they suspect was organised by a major international criminal syndicate.

Newcastle Herald

Experts insist personal drug use a health matter not something to jail people over

The endless cycle of the 'war on drugs'

1 … 133 134 135 136

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.